Silence Therapeutics (SLN) Current Assets (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Current Assets for 7 consecutive years, with $118.7 million as the latest value for Q4 2025.
- Quarterly Current Assets fell 36.67% to $118.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.7 million through Dec 2025, down 36.67% year-over-year, with the annual reading at $118.7 million for FY2025, 36.67% down from the prior year.
- Current Assets hit $118.7 million in Q4 2025 for Silence Therapeutics, down from $133.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $187.4 million in Q4 2024 to a low of $100.6 million in Q4 2023.
- Historically, Current Assets has averaged $136.0 million across 5 years, with a median of $126.1 million in 2025.
- Biggest five-year swings in Current Assets: skyrocketed 86.32% in 2024 and later plummeted 36.67% in 2025.
- Year by year, Current Assets stood at $116.4 million in 2021, then fell by 2.55% to $113.4 million in 2022, then dropped by 11.33% to $100.6 million in 2023, then surged by 86.32% to $187.4 million in 2024, then tumbled by 36.67% to $118.7 million in 2025.
- Business Quant data shows Current Assets for SLN at $118.7 million in Q4 2025, $133.6 million in Q3 2025, and $148.6 million in Q2 2025.